Cancer Support Community Celebrates Community Gives Day
June 17, 2021 14:26 ET | Cancer Support Community
WASHINGTON, D.C., June 17, 2021 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC), the world’s largest provider of cancer support with a network that operates at 175 locations, is announcing...
The Cancer Support Community Calls Supreme Court Decision a Victory for Patients
June 17, 2021 11:40 ET | Cancer Support Community
WASHINGTON, D.C., June 17, 2021 (GLOBE NEWSWIRE) -- Today, the U.S. Supreme Court, in a 7-2 decision, upheld the Affordable Care Act (ACA) in California v. Texas.   The ACA is a critical safety...
logo.jpg
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
June 17, 2021 09:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP)...
Onconova Logo BLUE.jpg
Onconova Therapeutics Announces the Peer-Reviewed Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined with Immune Checkpoint Blockade
June 17, 2021 08:00 ET | Onconova Therapeutics, Inc.
Rigosertib synergistically combined with immune checkpoint blockade (ICB) to improve tumor growth inhibition and survival in a murine melanoma model that did not respond to ICB alone Rigosertib’s...
Starton logo-pantone2112C.jpg
Starton Therapeutics Phase 2 TROPIC-I Clinical Study will be First to Use Total Control Primary Endpoint in Superiority Study
June 16, 2021 08:00 ET | Starton Therapeutics, Inc.
PARAMUS, N.J., June 16, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company transforming standard of care therapies with...
Aprea logo 445pt.png
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
June 16, 2021 08:00 ET | Aprea Therapeutics
37% CR rate in 30 efficacy-evaluable patients BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and...
MacroGenics-Logo-(transparent-background).png
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
June 16, 2021 07:30 ET | MacroGenics, Inc.
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific moleculesMacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific...
Cytovia.png
William Sullivan, CPA, MBA joins Cytovia Therapeutics as Chief Financial Officer
June 15, 2021 13:21 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., June 15, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
PDS Biotech Logo.png
PDS Biotech Prices Public Offering of Common Stock
June 15, 2021 09:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer...
logo.png
Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib
June 14, 2021 07:00 ET | Allarity Therapeutics A/S
  Oncoheroes will fund and advance clinical development of both dovitinib and stenoparib in pediatric cancersAllarity is preparing to file a first U.S. new drug application (NDA) for the approval...